PharmAbcine Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 0.00018 million. Net loss was KRW 30,548.46 million compared to KRW 44,033.34 million a year ago.

Basic loss per share from continuing operations was KRW 1,190 compared to KRW 2,126 a year ago. Diluted loss per share from continuing operations was KRW 1,190 compared to KRW 2,126 a year ago. Basic loss per share was KRW 1,190 compared to KRW 2,126 a year ago.